Cetuximab News and Research

RSS
Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.
Understanding Monoclonal Antibody Unfolding and Aggregation

Understanding Monoclonal Antibody Unfolding and Aggregation

Study: Checkpoint inhibitor prolongs survival in patients with head and neck cancers

Study: Checkpoint inhibitor prolongs survival in patients with head and neck cancers

Repurposed quinacrine can reduce tumor burden in mice bearing HNSCC xenograft tumors

Repurposed quinacrine can reduce tumor burden in mice bearing HNSCC xenograft tumors

Triplet therapy could benefit patients with BRAF-mutant metastatic colorectal cancer

Triplet therapy could benefit patients with BRAF-mutant metastatic colorectal cancer

New trial shows improved survival for patients with advanced colorectal BRAF-mutant cancer

New trial shows improved survival for patients with advanced colorectal BRAF-mutant cancer

Study: Three-drug combination improves overall survival in patients with mCRC

Study: Three-drug combination improves overall survival in patients with mCRC

New drug combinations and dosing schedules improve outlook in advanced colon cancer

New drug combinations and dosing schedules improve outlook in advanced colon cancer

Identifying colorectal cancer subtypes in patients could help provide better care

Identifying colorectal cancer subtypes in patients could help provide better care

Identifying subtype of colorectal cancer may help oncologists determine most effective treatment

Identifying subtype of colorectal cancer may help oncologists determine most effective treatment

New analysis reveals precision oncology insights for colorectal cancer

New analysis reveals precision oncology insights for colorectal cancer

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Toxic effects of drugs in the lungs 'more widespread than thought'

Toxic effects of drugs in the lungs 'more widespread than thought'

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

New model could predict personalized waiting time for progression in colorectal cancer

New model could predict personalized waiting time for progression in colorectal cancer

'Plastic antibodies' effectively target and eliminate tumor cells

'Plastic antibodies' effectively target and eliminate tumor cells

Clinical study suggests new treatment direction for head and neck cancer in heavy smokers

Clinical study suggests new treatment direction for head and neck cancer in heavy smokers

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Researchers develop new methods for studying evolution of cancer treatment resistance

Researchers develop new methods for studying evolution of cancer treatment resistance

Colorado researchers suggest new combination therapy for advanced head and neck cancer

Colorado researchers suggest new combination therapy for advanced head and neck cancer